In our study, among all antidiabetic drugs, only metformin displayed a decreasing effect on BNP levels, making metformin the first agent of choice in the treatment of diabetic patients at risk of cardiovascular disease. The gene discussed is NPPB; the disease is cardiovascular disorder.